Lindsay B D, Saksena S, Rothbart S T, Herman S, Barr M J
Am J Cardiol. 1987 Aug 31;60(6):63D-67D. doi: 10.1016/0002-9149(87)90711-9.
The efficacy and safety of nadolol and atenolol, 2 new long-acting beta-adrenergic receptor antagonists, were evaluated in patients with recurrent supraventricular tachycardia (SVT). Intravenous and oral drug therapy was administered to patients with atrioventricular reentrant tachycardia and atrioventricular nodal reentrant tachycardia. Efficacy was judged on a short-term basis by programmed electrical stimulation and on a long-term basis by clinical parameters and serial ambulatory electrocardiographic recordings during long-term follow-up. In addition, the usefulness of programmed electrical stimulation to predict long-term efficacy was evaluated. Intravenous nadolol prevented induction of SVT in 6 of 8 (75%) patients with atrioventricular nodal reentrant tachycardia, and oral nadolol prevented induction of SVT in 5 of 6 (83%) responders to intravenous nadolol. No episodes of sustained SVT recurred in these 5 patients during follow-up. Intravenous nadolol also prevented induction of SVT in 2 of 17 (11%) patients with atrioventricular reentrant tachycardia. Both patients remained non-inducible during treatment with oral nadolol, and neither experienced recurrence of SVT during follow-up. Intravenous atenolol prevented induction of SVT in 5 of 6 (83%) patients with atrioventricular nodal reentrant tachycardia. Oral atenolol prevented induction of atrioventricular nodal reentrant tachycardia in 4 of 5 (80%) patients responding to intravenous atenolol, and none of these 4 patients experienced a clinical recurrence. Intravenous atenolol prevented induction of SVT in 1 of 4 (25%) patients with atrioventricular reentrant tachycardia. Oral atenolol prevented induction of SVT in this patient and the arrhythmia has not recurred during follow-up. During follow-up (1 to 37 months), drug tolerance and compliance have been excellent with a low incidence of adverse reactions (11%).(ABSTRACT TRUNCATED AT 250 WORDS)
对两种新型长效β-肾上腺素能受体拮抗剂纳多洛尔和阿替洛尔在复发性室上性心动过速（SVT）患者中的疗效和安全性进行了评估。对房室折返性心动过速和房室结折返性心动过速患者给予静脉和口服药物治疗。短期疗效通过程控电刺激判断，长期疗效通过长期随访期间的临床参数和连续动态心电图记录判断。此外，还评估了程控电刺激预测长期疗效的实用性。静脉注射纳多洛尔可使8例房室结折返性心动过速患者中的6例（75%）不能诱发SVT，口服纳多洛尔可使6例静脉注射纳多洛尔有反应的患者中的5例（83%）不能诱发SVT。这5例患者在随访期间均未再发生持续性SVT。静脉注射纳多洛尔还可使17例房室折返性心动过速患者中的2例（11%）不能诱发SVT。这2例患者在口服纳多洛尔治疗期间均不能诱发心动过速，且在随访期间均未发生SVT复发。静脉注射阿替洛尔可使6例房室结折返性心动过速患者中的5例（83%）不能诱发SVT。口服阿替洛尔可使5例静脉注射阿替洛尔有反应的患者中的4例（80%）不能诱发房室结折返性心动过速，这4例患者均未出现临床复发。静脉注射阿替洛尔可使4例房室折返性心动过速患者中的1例（25%）不能诱发SVT。口服阿替洛尔可使该患者不能诱发SVT，且心律失常在随访期间未复发。在随访期间（1至37个月），药物耐受性和依从性良好，不良反应发生率低（11%）。（摘要截选至250字）
